# Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy

> **NCT00676507** · PHASE3 · COMPLETED · sponsor: **NovaRx Corporation** · enrollment: 532 (actual)

## Conditions studied

- Lung Neoplasm
- Carcinoma Non-small Cell Lung Cancer Stage IIIA
- Carcinoma Non-small Cell Lung Cancer Stage IIIB
- Carcinoma Non-small Cell Lung Cancer Stage IV

## Interventions

- **BIOLOGICAL:** Lucanix™
- **OTHER:** Placebo Comparator

## Key facts

- **NCT ID:** NCT00676507
- **Lead sponsor:** NovaRx Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 532 (ACTUAL)
- **Last updated:** 2015-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00676507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00676507, "Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT00676507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*